New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
June 3, 2014
09:06 EDTAEIS, KKD, NPSP, RNA, SSNLF, ZQK, PPC, IDCC, HSH, TSNOn The Fly: Pre-market Movers
HIGHER: InterDigital (IDCC), up 9.6% after announcing patent license agreement with Samsung (SSNLF), issuing Q2 revenue guidance... Hillshire Brands (HSH), up 8.8% after Pilgrim's Pride (PPC) raises buyout offer to $55 per share and Hillshire board authorizes talks with Pilgrim's and rival bidder Tyson Foods (TSN)... Prosensa (RNA), up 5.8% after announcing FDA regulatory path outline for DMD drug drisapersen. LOWER: Quiksilver (ZQK), down 39% after downgraded at Monness Crespi and at Stifel after the company's Q2 results and guidance disappointed... Krispy Kreme (KKD), down 10.5% after lowering its fiscal year guidance... Clovis (CLVS), down 11.9% after shares were downgraded to Neutral from Buy at Citigroup... Advanced Energy (AEIS), down 9.3% after downgraded at Needham following news that the company's CEO Garry Rogerson will step down... NPS Pharmaceuticals (NPSP), down 1.8% after saying in a regulatory filing that the company has not had any communication with Shire (SHPG) concerning an acquisition as stated in "erroneous press reports."
News For HSH;PPC;TSN;IDCC;KKD;ZQK;RNA;AEIS;SSNLF;NPSP From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
1 | 2 | 3 | 4 | all recent news | >>
January 12, 2015
10:00 EDTNPSPOn The Fly: Analyst Downgrade Summary
Subscribe for More Information
09:30 EDTNPSPOn The Fly: Pre-market Movers
HIGHER: Foundation Medicine (FMI) up 138.9% following transaction with Roche (RHHBY)... Celator Pharmaceuticals (CPXX), up 19.1% after announcing promising Phase 2 data for CPX-351... Second Sight (EYES), up 16.7% after Health Canada approves Argus II retinal prosthesis system... Aegerion (AEGR), up 7.8% after reporting preliminary fourth quarter results and guidance... Express (EXPR), up 4.5% after reporting preliminary fourth quarter results. NOTABLE: NPS Pharmaceuticals (NPSP), up 8.5% following acquisition by Shire (SHPG)... Shire is down 1.1% in pre-market trading. LOWER: Arrowhead (ARWR), down 20.9% after FDA clears company to begin modified study of ARC-520 in a preliminary call of a partial clinical hold... Tiffany (TIF), down 10.4% after lowering fiscal 2014 net EPS guidance... SanDisk (SNDK), down 10.1% after lowering fourth quarter outlook... Ascena Retail (ASNA), down 5.8% after lowering fiscal 2015 adjusted EPS view... Sarepta Therapeutics (SRPT), down 5.9% after reporting long-term outcomes from Phase IIb Eteplirsen study... Loral Space & Communications (LORL), down 3.6% following a NY Post article that reported that talks to sell itself to the Ontario Teachers’ Pension Plan have ended... Southwestern Energy (SWN), down 4.2% after filing to sell 20.3M shares of stock and 26M depository shares.
09:09 EDTKKDKrispy Kreme names Price Cooper as CFO
Krispy Kreme Doughnuts (KKD) that Price Cooper will be joining Krispy Kreme as EVP later this month. Cooper will be appointed CFO following the company’s filing of its Annual Report on Form 10-K in early April. Cooper will succeed Douglas R. Muir, who has served as CFO since June 2007 and who announced his retirement plans last year. Cooper previously served as CFO of Texas Roadhouse (TXRH).
09:02 EDTKKDTexas Roadhouse says CFO Price Cooper resigns
Subscribe for More Information
08:47 EDTNPSPShire acquisition favorable, says RBC Capital
Subscribe for More Information
08:37 EDTNPSPShire deal suggests most biotech companies in play, says JMP Securities
After Shire (SHPG) agreed to buy NPS Pharmaceuticals (NPSP), JMP Securities says the deal indicates that most biotech companies are in play, particularly those with worldwide rights to their products for well-defined patient populations. The firm expects investors to speculate all week about potential new targets in the space. Publicly traded companies in the space include AstraZeneca (AZN), Bristol-Myers (BMY), Eli Lilly (LLY), GlaxoSmithKline (GSK), Johnson & Johnson (JNJ), Merck (MRK), Novartis (NVS), Pfizer (PFE), Roche (RHHBY) and Sanofi (SNY).
08:14 EDTNPSPShire acquisition positive, says SunTrust
Subscribe for More Information
08:10 EDTKKDKrispy Kreme sees FY16 EPS 79c-85c, consensus 87c
Subscribe for More Information
08:09 EDTKKDKrispy Kreme backs FY15 EPS view 69c-74c, consensus 72c
Subscribe for More Information
08:00 EDTNPSPShire deal for NPS Pharmaceuticals positive, says Susquehanna
Subscribe for More Information
07:56 EDTNPSPShire price target raised to $257 from $223 at William Blair
Subscribe for More Information
07:55 EDTNPSPNPS Pharmaceuticals downgraded to Neutral from Outperform at Wedbush
Subscribe for More Information
07:46 EDTKKDStephens Events at 17th Annual ICR XChange Conference
Subscribe for More Information
07:26 EDTKKDWedbush to hold a meetings at ICR XChange Conference
Subscribe for More Information
07:20 EDTKKDICR to hold a conference
17th Annual ICR XChange Conference is being held in Orlando, Florida on January 12-14.
07:11 EDTNPSPNPS Pharmaceuticals volatility elevated into being acquired by Shire in a $5.2B
Subscribe for More Information
06:48 EDTNPSPNPS Pharmaceuticals downgraded to Hold from Buy at Canaccord
Subscribe for More Information
06:34 EDTSSNLFSamsung expected to launch two versions of Galaxy S6 phone in March, BI reports
Samsung will launch two versions of its Galaxy S6 phone in March at the Mobile World Congress, Business Insider reports, citing sources. One version will be made with metal, a departure from the plastic casings used in most Galaxy phones, while the other will have a curved screen, the sources say. Reference Link
06:11 EDTSSNLFSamsung, Pattern Energy complete wind energy project in Ontario
Subscribe for More Information
January 11, 2015
11:08 EDTNPSPShire acquires NPS Pharmaceuticals for $46 per share or $5.2B
Shire (SHPG) and NPS Pharmaceuticals (NPSP) announced that the companies have entered into a merger agreement pursuant to which Shire will acquire all the outstanding shares of NPS Pharma for $46.00 per share in cash, for a total consideration of approximately $5.2B. Shire said it "will accelerate the growth of NPS Pharma's innovative portfolio through its market expertise in gastrointestinal disorders, core capabilities in rare disease patient management, and global footprint." The transaction has been approved unanimously by the boards of both Shire and NPS Pharma. The $46 per share price in the transaction represents a 51% premium to NPS Pharma's unaffected share price of $30.47 on December 16, 2014. The acquisition is expected to enhance Shire's revenue and earnings growth profile. Shire expects the transaction to be accretive to non-GAAP earnings from 2016 onward. Related to the acquisition, Shire anticipates that it will realize operating synergies beginning in 2016 and growing "substantially" thereafter. Shire anticipates synergies approximating 25%-35% of the Street's consensus forecast of NPS Pharma's standalone future operating cost base from 2017 onward. Shire also expects that the transaction will deliver ROIC in excess of its weighted average cost of capital. Shire has secured an $850M fully underwritten short-term bank facility, which, in addition to Shire's cash and cash equivalents and its existing $2.1B five-year revolving credit facility, is available to finance the transaction and pay related fees and expenses. Shire plans to refinance the short-term bank facility through new debt issuances in "due course." The closing of the deal is anticipated in Q1 of 2015. Shares of NPS closed Friday down $1.01 to $41.91.
1 | 2 | 3 | 4 | all recent news | >>

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use